Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 17/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | BUB1 | O43683 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6215182 | 0.93 | ADORA3 (0.57) | PDE5AADORA3KCNH2 | |
| SCHEMBL6156803 | 0.88 | ADORA3 (0.54) | PDE5AADORA3KCNH2BUB1 | |
| SCHEMBL6217157 | 0.88 | ADORA3 (0.61) | PDE5AADORA3KCNH2 | |
| SCHEMBL15116987 | 0.83 | PDE5A (0.56) | PDE5AADORA3KCNH2 | |
| SCHEMBL5776111 | 0.83 | ADORA3 (0.62) | PDE5AADORA3KCNH2 | |
| SCHEMBL5104813 | 0.83 | PDE5A (0.63) | PDE5AADORA3KCNH2 | |
| SCHEMBL18496415 | 0.81 | PDE5A (0.59) | PDE5AADORA3KCNH2 | |
| SCHEMBL16594600 | 0.80 | ADORA3 (0.57) | PDE5AADORA3KCNH2 | |
| Etriciguat SCHEMBL419874 | 0.80 | ADORA3 (0.56) | PDE5AADORA3KCNH2BUB1 | |
| SCHEMBL25688767 | 0.80 | PDE5A (0.57) | PDE5AADORA3KCNH2BUB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1343786-B1 | NOVEL PYRIDINE-SUBSTITUTED PYRAZOLOPYRIDINE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2005-06-29 | — | — | EP | disclosed |
| EP-1499369-A1 | STENTS CONTAINING PYRIDINE-SUBSTITUTED PYRAZOLOPYRIDINE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2005-01-26 | — | — | EP | disclosed |
| US-6693102-B2 | CARDIOVASCULAR DISORDERS; HYPOTENSIVE AGENTS; CENTRAL NERVOUS SYSTEM DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 2004-02-17 | — | — | US | disclosed |
| WO-2003089024-A1 | STENTS CONTAINING PYRIDINE-SUBSTITUTED PYRAZOLOPYRIDINE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2003-10-30 | — | — | WO | disclosed |
| WO-2003086407-A1 | USE OF STIMULATORS OF SOLUBLE GUANYLATE CYCLASE FOR TREATING GLAUCOMA | BAYER HEALTHCARE AG (DE) | 2003-10-23 | — | — | WO | disclosed |
| EP-1343786-A1 | NOVEL PYRIDINE-SUBSTITUTED PYRAZOLOPYRIDINE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2003-09-17 | — | — | EP | disclosed |
| US-20020173514-A1 | Pyridine-substituted pyrazolopyridine derivatives | BAYER HEALTHCARE AG (DE) | 2002-11-21 | — | — | US | disclosed |
| WO-2002042301-A1 | NOVEL PYRIDINE-SUBSTITUTED PYRAZOLOPYRIDINE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173514-A1 | Pyridine-substituted pyrazolopyridine derivatives | GUCY1A1, GUCY1A2, GUCY1B1 | PDE5A 6/4885ADORA3 448/4885KCNH2 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.